| Drug General Information |
| Drug ID |
D0D0YM
|
| Former ID |
DIB002566
|
| Drug Name |
Amosulalol
|
| Synonyms |
Lowgan; LY-137224; YM-09538
|
| Drug Type |
Small molecular drug
|
| Indication |
Hypertension [ICD9: 401; ICD10:I10-I16]
|
Approved |
[1]
|
|---|
| Company |
Yamanouchi Pharmaceutical Co Ltd
|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C18H25ClN2O5S
|
| Canonical SMILES |
S(=O)(=O)(c1cc(ccc1C)C(O)CNCCOc1c(OC)cccc1)N
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
Beta-3 adrenergic receptor |
Target Info |
Modulator |
[1],
[2]
|
|---|
| Alpha-2C adrenergic receptor |
Target Info |
Modulator |
[1],
[2]
|
|
KEGG Pathway
|
Calcium signaling pathway
|
|
cGMP-PKG signaling pathway
|
|
Neuroactive ligand-receptor interaction
|
|
Endocytosis
|
|
Salivary secretionhsa04022:cGMP-PKG signaling pathway
|
|
PANTHER Pathway
|
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
|
Beta3 adrenergic receptor signaling pathwayP00002:Alpha adrenergic receptor signaling pathway
|
|
Reactome
|
Adrenoceptors
|
|
G alpha (s) signalling eventsR-HSA-390696:Adrenoceptors
|
|
Adrenaline signalling through Alpha-2 adrenergic receptor
|
|
Adrenaline,noradrenaline inhibits insulin secretion
|
|
G alpha (i) signalling events
|
|
G alpha (z) signalling events
|
|
Surfactant metabolism
|
|
WikiPathways
|
Monoamine GPCRs
|
|
Calcium Regulation in the Cardiac Cell
|
|
GPCRs, Class A Rhodopsin-like
|
|
GPCR ligand binding
|
|
GPCR downstream signalingWP58:Monoamine GPCRs
|
|
Platelet Aggregation (Plug Formation)
|
|
Integration of energy metabolism
|
|
GPCR downstream signaling
|
| References |
| REF 1 | Effects of amosulalol, a combined alpha 1- and beta-adrenoceptor-blocking agent, on ischemic myocardial energy metabolism in dogs. J Pharm Sci. 1993 Mar;82(3):291-5. |
|---|
| REF 2 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 |
|---|
